IL23R-CAR-Treg / Sangamo Therap - LARVOL DELTA

IL23R-specific CAR Tregs for the treatment of Crohn's disease. (PubMed, J Crohns Colitis) - "Overall, our results demonstrate that IL23R-CAR Tregs represent a promising therapy for active CD."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology

Evaluation of IL23R as a target for CAR‐Treg at the site of inflammation in subjects with Crohn's Disease (ESGCT 2023) - "Finally, we performed molecular profiling of CD patients to support clinical development. Overall, we confirm that IL23R-CAR-Tregs are specifically activated by IL23R in the inflamed mucosa in CD and provide a promising treatment option for CD patients."

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

IL23R-CAR-Tregs: creating a therapeutic breakthrough for Crohn’s Disease (ECCO-IBD 2024) - "We also identified molecular profiles that correlated with IL23R-CAR activation and, more broadly, showed their potential to monitor IL23R-CAR-Treg activity in CD patients. Conclusion Our results demonstrate that an IL23R-CAR-Treg product could be a promising therapy for CD patients, with the potential long-term benefits of immune tolerance."

Crohn's disease • Immunology • Inflammatory Bowel Disease • FOXP3

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Businesswire) - "Sangamo Therapeutics, Inc...announced that the European Society of Gene & Cell Therapy (ESGCT) has accepted six Sangamo abstracts for presentation at the 30th Annual Congress being held October 24-27, 2023, in-person in Brussels, Belgium. Presentations will focus on the progression of Sangamo’s pre-clinical programs, including data from its neurology epigenetic regulation programs, and advancements in the CAR-Treg pipeline....updated pre-clinical data evaluating IL23R-CAR-Tregs as a potentially effective treatment option to address inflammation for patients with Crohn’s disease."

Preclinical • Crohn's disease • Immunology • Inflammatory Bowel Disease